3. Significant Strategic Drug Development Collaborations |
9 Months Ended |
|---|---|
Sep. 30, 2015 | |
| Research and Development [Abstract] | |
| Significant Strategic Drug Development Collaborations |
The Company had various research, development, license and supply agreements with Baxter Healthcare SA and Baxter Healthcare Corporation (together referred to as “Baxter”). During June 2015, in connection with the separation of its biopharmaceuticals business to form Baxalta Incorporated (“Baxalta”), Baxter assigned all of its rights and obligations under its existing agreement with the Company to Baxalta. Other than, with respect to the assignment to Baxalta, the Company’s agreements with Baxter will continue with full force and effect. In addition, the Company has various research, development, license and supply agreements with SynBio LLC (“SynBio”), Serum Institute of India (“Serum Institute”) and OJSC Pharmsynthez (“Pharmsynthez”). The Company and its collaborative partners continued to engage in research and development activities with no resultant commercial products through September 30, 2015. No amounts were recognized as revenue related to these agreements during the nine months ended September 30, 2015 or 2014. |